메뉴 건너뛰기




Volumn 17, Issue 7, 2015, Pages 630-638

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: A randomized, controlled study (GENERATION)

Author keywords

Dipeptidyl peptidase 4 inhibitor; Randomized trial; Sulphonylureas; Type 2 diabetes

Indexed keywords

GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; SAXAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE;

EID: 84931957004     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12461     Document Type: Article
Times cited : (56)

References (32)
  • 1
    • 30844455608 scopus 로고    scopus 로고
    • Diabetes in the elderly: considerations for clinical practice
    • Lecomte P. Diabetes in the elderly: considerations for clinical practice. Diabetes Metab 2005; 31: 5S105-111.
    • (2005) Diabetes Metab , vol.31 , pp. 5S105-5S111
    • Lecomte, P.1
  • 2
    • 78651338445 scopus 로고    scopus 로고
    • Standards of medical care in diabetes-2011
    • American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34: S11-61.
    • (2011) Diabetes Care , vol.34 , pp. S11-S61
  • 3
    • 79960959816 scopus 로고    scopus 로고
    • Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
    • Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M etal. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343: d4169.
    • (2011) BMJ , vol.343 , pp. d4169
    • Boussageon, R.1    Bejan-Angoulvant, T.2    Saadatian-Elahi, M.3
  • 4
    • 79952260576 scopus 로고    scopus 로고
    • Diabetes mellitus, fasting glucose, and risk of cause-specific death
    • Seshasai SR, Kaptoge S, Thompson A etal. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841.
    • (2011) N Engl J Med , vol.364 , pp. 829-841
    • Seshasai, S.R.1    Kaptoge, S.2    Thompson, A.3
  • 5
    • 84919999219 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-149.
    • (2015) Diabetes Care , vol.38 , pp. 140-149
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 6
    • 84976585919 scopus 로고    scopus 로고
    • Saxagliptin summary of product characteristics
    • Accessed 21 January
    • Bristol-Myers Squibb. Saxagliptin summary of product characteristics. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/001039/WC500044316.pdf. Accessed 21 January 2015.
    • (2015)
  • 7
    • 69549135336 scopus 로고    scopus 로고
    • The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone
    • DeFronzo RA, Hissa MN, Garber AJ etal. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32: 1649-1655.
    • (2009) Diabetes Care , vol.32 , pp. 1649-1655
    • DeFronzo, R.A.1    Hissa, M.N.2    Garber, A.J.3
  • 8
    • 78349292168 scopus 로고    scopus 로고
    • Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial
    • Goke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010; 64: 1619-1631.
    • (2010) Int J Clin Pract , vol.64 , pp. 1619-1631
    • Goke, B.1    Gallwitz, B.2    Eriksson, J.3    Hellqvist, A.4    Gause-Nilsson, I.5
  • 9
    • 77958030736 scopus 로고    scopus 로고
    • Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
    • Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010; 26: 540-549.
    • (2010) Diabetes Metab Res Rev , vol.26 , pp. 540-549
    • Scheen, A.J.1    Charpentier, G.2    Ostgren, C.J.3    Hellqvist, A.4    Gause-Nilsson, I.5
  • 10
    • 84895836577 scopus 로고    scopus 로고
    • Saxagliptin (SAXA) effectively reduces hba1c and is well tolerated when added to a combination of metformin (MET) and sulfonylurea (SU)
    • Moses RG, Kalra S, Brook D, Sockler J, Visvanathan J, Fisher SA. Saxagliptin (SAXA) effectively reduces hba1c and is well tolerated when added to a combination of metformin (MET) and sulfonylurea (SU). Diabetes 2012; 61: A282.
    • (2012) Diabetes , vol.61 , pp. A282
    • Moses, R.G.1    Kalra, S.2    Brook, D.3    Sockler, J.4    Visvanathan, J.5    Fisher, S.A.6
  • 11
    • 79959211974 scopus 로고    scopus 로고
    • Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks
    • Chacra AR, Tan GH, Ravichandran S, List J, Chen R. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res 2011; 8: 150-159.
    • (2011) Diab Vasc Dis Res , vol.8 , pp. 150-159
    • Chacra, A.R.1    Tan, G.H.2    Ravichandran, S.3    List, J.4    Chen, R.5
  • 12
    • 79959217544 scopus 로고    scopus 로고
    • Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
    • Hollander PL, Li J, Frederich R, Allen E, Chen R. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 2011; 8: 125-135.
    • (2011) Diab Vasc Dis Res , vol.8 , pp. 125-135
    • Hollander, P.L.1    Li, J.2    Frederich, R.3    Allen, E.4    Chen, R.5
  • 13
    • 84885130771 scopus 로고    scopus 로고
    • Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy
    • Barnett AH, Charbonnel B, Li J, Donovan M, Fleming D, Iqbal N. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Clin Drug Investig 2013; 33: 707-717.
    • (2013) Clin Drug Investig , vol.33 , pp. 707-717
    • Barnett, A.H.1    Charbonnel, B.2    Li, J.3    Donovan, M.4    Fleming, D.5    Iqbal, N.6
  • 14
    • 84876221922 scopus 로고    scopus 로고
    • Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥65years) with inadequately controlled type 2 diabetes mellitus
    • Karyekar CS, Ravichandran S, Allen E, Fleming D, Frederich R. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥65years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging 2013; 8: 419-430.
    • (2013) Clin Interv Aging , vol.8 , pp. 419-430
    • Karyekar, C.S.1    Ravichandran, S.2    Allen, E.3    Fleming, D.4    Frederich, R.5
  • 15
    • 79952651976 scopus 로고    scopus 로고
    • Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus
    • Doucet J, Chacra A, Maheux P, Lu J, Harris S, Rosenstock J. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin 2011; 27: 863-869.
    • (2011) Curr Med Res Opin , vol.27 , pp. 863-869
    • Doucet, J.1    Chacra, A.2    Maheux, P.3    Lu, J.4    Harris, S.5    Rosenstock, J.6
  • 16
    • 84877586819 scopus 로고    scopus 로고
    • Diabetes control in older people
    • McLaren LA, Quinn TJ, McKay GA. Diabetes control in older people. BMJ 2013; 346: f2625.
    • (2013) BMJ , vol.346 , pp. f2625
    • McLaren, L.A.1    Quinn, T.J.2    McKay, G.A.3
  • 17
    • 84856751751 scopus 로고    scopus 로고
    • Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds
    • Zoungas S, Chalmers J, Ninomiya T etal. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012; 55: 636-643.
    • (2012) Diabetologia , vol.55 , pp. 636-643
    • Zoungas, S.1    Chalmers, J.2    Ninomiya, T.3
  • 18
    • 63149103614 scopus 로고    scopus 로고
    • Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
    • Skyler JS, Bergenstal R, Bonow RO etal. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009; 32: 187-192.
    • (2009) Diabetes Care , vol.32 , pp. 187-192
    • Skyler, J.S.1    Bergenstal, R.2    Bonow, R.O.3
  • 19
    • 84881416448 scopus 로고    scopus 로고
    • Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis
    • Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 2013; 347: f4533.
    • (2013) BMJ , vol.347 , pp. f4533
    • Goto, A.1    Arah, O.A.2    Goto, M.3    Terauchi, Y.4    Noda, M.5
  • 20
    • 84893115459 scopus 로고    scopus 로고
    • Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases
    • Stahn A, Pistrosch F, Ganz X etal. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases. Diabetes Care 2013; 37: 516-520.
    • (2013) Diabetes Care , vol.37 , pp. 516-520
    • Stahn, A.1    Pistrosch, F.2    Ganz, X.3
  • 21
    • 84862893115 scopus 로고    scopus 로고
    • Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes
    • Sinclair A, Morley JE, Rodriguez-Manas L etal. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc 2012; 13: 497-502.
    • (2012) J Am Med Dir Assoc , vol.13 , pp. 497-502
    • Sinclair, A.1    Morley, J.E.2    Rodriguez-Manas, L.3
  • 22
    • 84881189911 scopus 로고    scopus 로고
    • Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study
    • Strain WD, Lukashevich V, Kothny W, Hoellinger MJ, Paldanius PM. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet 2013; 382: 409-416.
    • (2013) Lancet , vol.382 , pp. 409-416
    • Strain, W.D.1    Lukashevich, V.2    Kothny, W.3    Hoellinger, M.J.4    Paldanius, P.M.5
  • 23
    • 84931958589 scopus 로고    scopus 로고
    • Glimepiride 4mg tablets: summary of product characteristics Accessed 21 January
    • Accord Healthcare. Glimepiride 4mg tablets: summary of product characteristics. Available from URL: http://www.medicines.org.uk/EMC/history/25845/SPC/Glimepiride+4+mg+Tablets. Accessed 21 January 2015.
    • (2015)
  • 24
    • 4344693381 scopus 로고    scopus 로고
    • GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients
    • Schernthaner G, Grimaldi A, Di MU etal. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004; 34: 535-542.
    • (2004) Eur J Clin Invest , vol.34 , pp. 535-542
    • Schernthaner, G.1    Grimaldi, A.2    Di, M.U.3
  • 25
    • 68149117576 scopus 로고    scopus 로고
    • Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes
    • Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009; 32: 1513-1517.
    • (2009) Diabetes Care , vol.32 , pp. 1513-1517
    • Bremer, J.P.1    Jauch-Chara, K.2    Hallschmid, M.3    Schmid, S.4    Schultes, B.5
  • 26
    • 0034797567 scopus 로고    scopus 로고
    • Symptoms of hypoglycaemia in people with diabetes
    • McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. Diabet Med 2001; 18: 690-705.
    • (2001) Diabet Med , vol.18 , pp. 690-705
    • McAulay, V.1    Deary, I.J.2    Frier, B.M.3
  • 27
    • 84895467669 scopus 로고    scopus 로고
    • Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials
    • Zhang Y, Hong J, Chi J, Gu W, Ning G, Wang W. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev 2014; 30: 241-256.
    • (2014) Diabetes Metab Res Rev , vol.30 , pp. 241-256
    • Zhang, Y.1    Hong, J.2    Chi, J.3    Gu, W.4    Ning, G.5    Wang, W.6
  • 28
    • 84883742095 scopus 로고    scopus 로고
    • Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study
    • Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab 2013; 15: 906-914.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 906-914
    • Rosenstock, J.1    Wilson, C.2    Fleck, P.3
  • 29
    • 84886297885 scopus 로고    scopus 로고
    • Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial
    • Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet 2013; 382: 1413-1423.
    • (2013) Lancet , vol.382 , pp. 1413-1423
    • Barnett, A.H.1    Huisman, H.2    Jones, R.3    von Eynatten, M.4    Patel, S.5    Woerle, H.J.6
  • 30
    • 84883765959 scopus 로고    scopus 로고
    • Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
    • Scirica BM, Bhatt DL, Braunwald E etal. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
    • (2013) N Engl J Med , vol.369 , pp. 1317-1326
    • Scirica, B.M.1    Bhatt, D.L.2    Braunwald, E.3
  • 31
    • 18144388647 scopus 로고    scopus 로고
    • Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia
    • American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-1249.
    • (2005) Diabetes Care , vol.28 , pp. 1245-1249
  • 32
    • 60449089649 scopus 로고    scopus 로고
    • Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Nathan DM, Buse JB, Davidson MB etal. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
    • (2009) Diabetes Care , vol.32 , pp. 193-203
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.